These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36526922)

  • 1. Ipsilateral hemigland prostate biopsy may underestimate cancer burden in patients with unilateral mpMRI-visible lesions.
    Phelps TE; Yilmaz EC; Harmon SA; Belue MJ; Shih JH; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
    Abdom Radiol (NY); 2023 Mar; 48(3):1079-1089. PubMed ID: 36526922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
    Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
    Kachanov M; Leyh-Bannurah SR; Roberts MJ; Sauer M; Beyersdorff D; Boiko S; Maurer T; Steuber T; Graefen M; Budäus L
    J Urol; 2022 Feb; 207(2):333-340. PubMed ID: 34555925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of clinically significant prostate cancer in biopsy-naïve men: direct comparison of systematic biopsy, multiparametric MRI- and contrast-ultrasound-dispersion imaging-targeted biopsy.
    Mannaerts CK; Engelbrecht MRW; Postema AW; van Kollenburg RAA; Hoeks CMA; Savci-Heijink CD; Van Sloun RJG; Wildeboer RR; De Reijke TM; Mischi M; Wijkstra H
    BJU Int; 2020 Oct; 126(4):481-493. PubMed ID: 32315112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy.
    Freifeld Y; Xi Y; Passoni N; Woldu S; Hornberger B; Goldberg K; Bagrodia A; Raj G; Margulis V; Cadeddu JA; Lotan Y; Francis F; Pedrosa I; G Roehrborn C; Costa DN
    Urol Oncol; 2019 Jan; 37(1):57-62. PubMed ID: 30446460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic efficacy of prostate cancer using targeted biopsy with 6-core systematic biopsy for patients with PI-RADS 5].
    Liu Y; Yuan CW; Wu JY; Shen Q; Xiao JX; Zhao Z; Wang XY; Li XS; He ZS; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):812-817. PubMed ID: 37807733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the optimal strategy in men with a single unilateral suspicious lesion on MRI undergoing transperineal MRI/ultrasound fusion prostate biopsy.
    Yusim I; Mazor E; Frumkin E; Jabareen M; Hefer B; Elsaraya N; Li S; Rouvinov K; Novack V; Mabjeesh NJ
    Prostate; 2023 Sep; 83(13):1255-1262. PubMed ID: 37263774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of clinically significant prostate cancer by transperineal multiparametric magnetic resonance imaging-ultrasound fusion targeted prostate biopsy in smaller prostates.
    Dahl DM; Kim MM; Wu S; Lin SX; Crotty RK; Cornejo KM; Harisinghani MG; Feldman AS; Wu CL
    Urol Oncol; 2022 Oct; 40(10):451.e9-451.e14. PubMed ID: 36008257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series.
    Stabile A; Barletta F; Motterle G; Pellegrino F; Sorce G; Mazzone E; Scuderi S; Cirulli GO; Cucchiara V; Esposito A; Gandaglia G; Fossati N; De Cobelli F; Montorsi F; Karnes RJ; Briganti A
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1137-1142. PubMed ID: 33941867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical available decision support scheme for optimizing prostate biopsy based on mpMRI.
    Hou Y; Jiang KW; Zhang J; Bao ML; Shi HB; Qu JR; Cheng G; Zhang YD
    Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):727-734. PubMed ID: 35067674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Accuracy of MRI-Ultrasound Fusion Targeted Biopsy Based on PI-RADS v2.1 Category in Transition/Peripheral Zone of the Prostate.
    Liu Y; Wang S; Xu G; Zhou B; Zhang Y; Ye B; Xiang L; Zhang Y; Xu H
    J Magn Reson Imaging; 2023 Sep; 58(3):709-717. PubMed ID: 36773016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy.
    Oderda M; Albisinni S; Benamran D; Calleris G; Ciccariello M; Dematteis A; Diamand R; Descotes JL; Fiard G; Forte V; Giacobbe A; Marquis A; Marra G; Messas A; Muto G; Peltier A; Rius L; Simone G; Roumeguere T; Faletti R; Gontero P
    Prostate; 2023 Feb; 83(2):162-168. PubMed ID: 36259316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer.
    Stabile A; Dell'Oglio P; Soligo M; De Cobelli F; Gandaglia G; Fossati N; Esposito A; Brembilla G; Karnes RJ; Montorsi F; Briganti A
    Eur Urol Oncol; 2021 Aug; 4(4):594-600. PubMed ID: 31204312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs: A prospective single center, randomized study.
    Porreca A; Del Giudice F; Giampaoli M; D'Agostino D; Romagnoli D; Corsi P; Del Rosso A; Maggi M; Chung BI; Ferro M; de Cobelli O; Lucarelli G; Schiavina R; De Berardinis E; Sciarra A; Busetto GM
    Medicine (Baltimore); 2020 Sep; 99(37):e22059. PubMed ID: 32925739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Biopsy With Reduced Number of Cores: Optimal Sampling Scheme in Patients Undergoing Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Prostate Biopsy.
    Shen WW; Cui LG; Ran WQ; Sun Y; Jiang J; Pei XL; Chen W
    Ultrasound Med Biol; 2020 May; 46(5):1197-1207. PubMed ID: 32107089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies.
    Jager A; van Riel LAMJG; Postema AW; de Reijke TM; van der Sluis TM; Oddens JR
    Ther Adv Urol; 2022; 14():17562872221111410. PubMed ID: 35924207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gleason Grade Group Concordance between Systematic Template Combining Magnetic Resonance Imaging Fusion Targeted Biopsy and Radical Prostatectomy Specimens: A Comparison of Transperineal and Transrectal Approaches.
    Wu S; Feldman AS; Kim MM; Lin SX; Cornejo KM; Harisinghani MG; Dahl DM; Wu CL
    Urology; 2023 May; 175():151-156. PubMed ID: 36828261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy.
    Mannaerts CK; Kajtazovic A; Lodeizen OAP; Gayet M; Engelbrecht MRW; Jager GJ; Wijkstra H; de Reijke TM; Beerlage HP
    Urol Oncol; 2019 May; 37(5):298.e1-298.e9. PubMed ID: 30660493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
    Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
    Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.